2 citations
,
October 2019 in “The Egyptian Journal of Hospital Medicine” This study found that anti-Müllerian hormone (AMH) showed high sensitivity and specificity as a diagnostic marker for polycystic ovary syndrome in the studied population, suggesting its promise as an objective diagnostic tool.
28 citations
,
September 2017 in “Gynecological Endocrinology” This study found that women with polycystic ovary syndrome had significantly higher serum and intrafollicular levels of anti-Müllerian hormone compared to normovulatory women, indicating a potential marker for ovarian hyperstimulation syndrome risk.
4 citations
,
May 2022 in “BMC Women's Health” This study found that elevated serum AMH levels can be a strong predictor for diagnosing PCOS among women of reproductive age, when used alongside the other Rotterdam criteria.
6 citations
,
January 2013 in “Journal of Clinical and Diagnostic Research” This study found that anti-mullerian hormone levels are significantly elevated in infertile women with polycystic ovarian syndrome compared to those with regular cycles, suggesting it as a potential marker for diagnosing PCOS-related infertility.
June 2026 in “Biomedical and Therapeutics Letters” This review discusses AMH and ovarian morphology as complementary markers in diagnosing PCOS/PMOS and reports no new clinical results, highlighting the need for a multidomain approach in diagnosis and treatment.